CSL (ASX:CSL) Insider Brian McNamee Acquires 433 Shares of Stock

CSL Limited (ASX:CSL) insider Brian McNamee acquired 433 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was bought at an average price of A$151.56 per share, with a total value of A$65,625.05.

CSL Price Performance

The company has a debt-to-equity ratio of 64.46, a quick ratio of 1.68 and a current ratio of 1.86. The firm has a market cap of $77.43 billion, a price-to-earnings ratio of 28.02, a P/E/G ratio of 1.29 and a beta of 0.32.

CSL Dividend Announcement

The firm also recently declared a Interim dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Wednesday, April 8th will be paid a $1.837 dividend. The ex-dividend date is Monday, March 9th. This represents a yield of 121.0%. CSL’s dividend payout ratio (DPR) is currently 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.